Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal

Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up to $139 million.